Top Markets
#1 Pleasing Gold Pleasing Gold +656.39%
#2 Islamic Coin Islamic Coin +154.16%
#3 PulseChain PulseChain +56.20%
#4 BOOK OF MEME BOOK OF MEME +42.24%
#5 DogBull DogBull +37.63%
#6 Neiro Neiro +21.68%
#7 Collect on Fanable Collect on Fanable +21.03%
#8 Nockchain Nockchain +17.26%
#9 PondCoin PondCoin +16.48%
#10 rsERG rsERG +16.48%
Coin of the day
Pleasing Gold Pleasing Gold
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Cytocom, Inc. Cytocom, Inc.

Cytocom, Inc.

CBLI
Classement en actions #27145
Cleveland BioLabs, Inc. functions as a biopharmaceutical firm, specializing in... Cleveland BioLabs, Inc. functions as a biopharmaceutical firm, specializing in the discovery and advancement of therapeutic drugs. Based in Buffalo, New York, the organization maintains a modest workforce of 15 full-time employees. Its primary objective involves pioneering methods to stimulate the body's immune defenses to tackle significant medical challenges. A core component of its work is a platform utilizing Toll-like immune receptor activators, which demonstrates utility in both alleviating radiation-induced damage and in the field of immuno-oncology. The most advanced therapeutic candidate in its pipeline is Entolimod, an immune-stimulating compound currently under development as a protective measure against radiation exposure and as an immunotherapy for various cancers and other indications. The company's portfolio also encompasses other promising products, including CBLB612, Mobilan, and CBL0137. CBLB612 is formulated from a natural stimulant that targets a specific component of the innate immune system: the heterodimeric receptor formed by toll-like receptors 2 (TLR2) and 6 (TLR6). Mobilan is a recombinant, non-replicating adenovirus engineered to induce the expression of TLR5 and its corresponding agonistic ligand. Lastly, CBL0137 is a small molecule characterized by a multi-faceted mechanism of action, suggesting its potential effectiveness across diverse forms of cancer.
Prix de l'action
$3.17
Dernière synchronisation: 2021-08-31
Capitalisation boursière
$34.83M
Changement (1 jour)
-7.31%
Changement (1 an)
0.00%
Pays
US
Échange Cytocom, Inc. (CBLI)

Catégorie

Healthcare
Ratio P/S pour Cytocom, Inc. (CBLI)
Ratio P/S au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de Cytocom, Inc., le ratio cours/ventes actuel (TTM) est 0. À la fin de 2026, le ratio P/S était de 0.
Historique du ratio P/S pour Cytocom, Inc. de 2026 à 2026
Ratio P/S à la fin de chaque année
Année Ratio P/S Changez
Pas assez de données pour les dates fournies.
Ratio P/S pour des entreprises similaires ou concurrentes
Entreprise Ratio P/S Différence de Ratio P/S Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.17 -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
11.28 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.13 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
2.95 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH